Cadila Pharmaceuticals reaffirms commitment to patient safety and regulatory compliance
Mumbai : Cadila Pharmaceuticals, a leading research-driven pharmaceutical company, has reaffirmed its commitment to patient safety following a recent regulatory communication concerning its Aciloc range.
Cadila Pharmaceuticals reiterated that the active pharmaceutical ingredient has always been clearly and prominently declared on the packaging and labels of all Aciloc products in accordance with applicable regulatory requirements. The company’s scientific and regulatory teams are engaging with the relevant authorities and examining the matter in detail.
Dr. Arani Chatterjee, President Cadila Pharmaceuticals Limited said, “Patient safety remains our highest priority. The active pharmaceutical ingredient is clearly stated on every Aciloc pack in accordance with applicable regulatory requirements. We are working closely with the relevant authorities, extending our full cooperation and reviewing the matter carefully. We remain committed to ensuring continued confidence in the quality, safety and appropriate use of our medicines.”
The company further clarified that Aciloc 150+ and Aciloc 300+ belong to the same therapeutic class of H2 receptor antagonists, with the respective active ingredients clearly identified on every pack in accordance with regulatory requirements.
For more than 75 years, Cadila Pharmaceuticals has been a pioneer in the Indian healthcare industry, developing high-quality, affordable medicines while adhering to applicable regulatory standards, robust quality systems and ethical business practices.
Cadila Pharmaceuticals reiterated that it remains committed to maintaining the highest standards of quality, patient safety and regulatory compliance, and will continue to work constructively with the relevant authorities.
